Gilead Sciences Announces Issuance of $3.5B Senior Notes

Details

announced the issuance of $3.5 billion in aggregate principal amount of senior notes due between 2029 and 2064. The proceeds will be used for general corporate purposes, including the repayment of indebtedness. The issuance is subject to certain restrictions outlined in the Tenth Supplemental Indenture to the Base Indenture, dated March 30, 2011. The notes will pay interest semi-annually at varying rates until their respective maturity dates. Gilead Sciences also entered into an underwriting agreement with Barclays Capital Inc. and BofA Securities, Inc. for the issuance and sale of these notes.

Items reported

Exhibits (3)

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.